Effects of liraglutide on metabolic syndrome in WBN/Kob diabetic fatty rats supplemented with a high‐fat diet
Abstract Background Liraglutide, a GLP‐1 receptor agonist, has recently been used to treat metabolic syndrome (MS) because of its anti‐diabetic and anti‐obesity effects. We have previously shown that Wistar Bonn Kobori diabetic and fatty (WBN/Kob‐Leprfa, WBKDF) rats fed a high‐fat diet (HFD) develop...
Main Authors: | Noriyuki Kaji, Yoshiichi Takagi, Satomi Matsuda, Anna Takahashi, Sakurako Fujio, Fumitoshi Asai |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-03-01
|
Series: | Animal Models and Experimental Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/ame2.12106 |
Similar Items
-
High-Salt Intake Ameliorates Hyperglycemia and Insulin Resistance in WBN/Kob-Leprfa/fa Rats: A New Model of Type 2 Diabetes Mellitus
by: Yoshiichi Takagi, et al.
Published: (2018-01-01) -
Liraglutide overdose: A case report and an updated review
by: Sharafaldeen Bin Nafisah, et al.
Published: (2020-01-01) -
Efficacy and safety of liraglutide in Indian adolescents with obesity
by: I. S. Kochar, et al.
Published: (2019-06-01) -
Liraglutide-induced injection site reaction
by: Nada Fouda Neel, et al.
Published: (2019-01-01) -
Role of liraglutide in Alzheimer’s disease pathology
by: Maria Vargas-Soria, et al.
Published: (2021-06-01)